World Journal of
Pharmaceutical and Life Sciences

LC–MS–ANALYTICAL AND PHARMACODYNAMIC EXPLORATION OF VINFLUNINE IN EYE CANCER CELL LINE MODELS

Somabatthini Shruthi*, Dr. Syed Ahmed Hussain, Ghousia Begum, Nada Ahmed Al Amoodi, Fariya Sultana, Bilquis Begum, Ayesha Ayub Khan, Muskan Khatoon

ABSTRACT

This study investigates the comparative in vitro efficacy of Vinflunine and Vinblastine in eye cancer cell line models, including retinoblastoma (Y79, WERI-Rb1) and uveal melanoma (OCM-1, 92.1). A five-assay evaluation panel was employed to quantify cell viability and cytotoxicity. In metabolic assays (Resazurin/Alamar Blue and ATP Luminescence), Vinflunine retained 80–82% viability relative to vehicle, suggesting moderate antiproliferative activity, while Vinblastine maintained full viability (100%). In cytotoxicity assays, Vinflunine induced 23% apoptosis, 1.7-fold Caspase-3/7 activation, and 21% LDH release—reflecting mild but measurable apoptotic engagement. Vinblastine, by contrast, showed minimal cytotoxic response (7%, 1.0-fold, and 8%, respectively). These findings highlight that Vinflunine exerts controlled apoptotic and cytostatic effects, potentially linked to its fluorinated structural modification, enhancing tubulin interaction. Overall, Vinflunine demonstrated a superior apoptotic signature and modest cytotoxic efficiency compared to Vinblastine, supporting its exploration as a low-toxicity candidate for ocular chemotherapeutic applications.

[Full Text Article]   [Download Certificate]